Adjuvant radiotherapy versus observation alone, after radical prostatectomy in high risk prostate cancer
| Autor: | Luiz Antonio Negrão Dias, Lais Cristine Nienkotter, Massakazu Kato, Luis Felipe Matiusso de Souza, Murilo Luz, Andrea Petruzziello |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
Male
medicine.medical_specialty recurrence medicine.medical_treatment Urology Disease-Free Survival prostatic neoplasms Prostate cancer medicine Humans radioterapia adjuvante Watchful Waiting Aged Neoplasm Staging Retrospective Studies recidiva Prostatectomy Adjuvant radiotherapy lcsh:R5-920 prostatectomy business.industry neoplasias da próstata Follow up studies Prostatic Neoplasms Retrospective cohort study General Medicine Prostate-Specific Antigen medicine.disease Surgery Prostate-specific antigen Treatment Outcome Disease Progression Radiotherapy Adjuvant Positive Surgical Margin prostatectomia business lcsh:Medicine (General) adjuvant radiotherapy Watchful waiting Follow-Up Studies |
| Zdroj: | Revista da Associação Médica Brasileira v.61 n.4 2015 Revista da Associação Médica Brasileira Associação Médica Brasileira (AMB) instacron:AMB Revista da Associação Médica Brasileira, Vol 61, Iss 4, Pp 324-328 (2015) |
| Popis: | SummaryObjectives:the authors compared biochemical and clinical outcomes of patients with resected high-risk prostate cancer, managed with adjuvant radiotherapy or observation alone.Methods:patients treated with radical prostatectomy (RP) between January 1995 and December 2005 at the authors’ department were evaluated. Patients with pT3, with or without positive surgical margins (PSM), were included for analysis. Demographic, clinical, pathologic and follow-up data were recorded. Comparison was made between adjuvant radiotherapy group (AR) and observation alone group (OA). Primary end-point was biochemical progression-free survival.Results:out of 739 patients treated with RP, 49 presented with pT3 with or without PSM. 39 received adjuvant radiotherapy and 10 were observed. Median follow- up was 6.2 years for AR and 7.3 years for OA. Biochemical progression occurred in 12.8%, in AR, and 70%, in OA (p=0.0008). Five-year biochemical progression-free survival was 87.1% in AR and 30% in OA (HR 0.12, 95% CI 0.03- 0.48 – p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|